Scarica l'app Stockscreener
6.71
2.19%
-0.15
Dopo l'orario di chiusura:
6.73
0.02
+0.30%
Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie
Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week - simplywall.st
Why Trevi Therapeutics Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser
How Trevi Therapeutics Inc. stock performs during market volatilitySteady Profit Stock Forecasts - Newser
What makes Trevi Therapeutics Inc. stock price move sharplyFree Stock Market Analysis Courses - Newser
Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis - The Globe and Mail
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know - Yahoo Finance
31,359 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Purchased by Vontobel Holding Ltd. - Defense World
Cantor Fitzgerald Comments on TRVI FY2025 Earnings - Defense World
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism | TRVI Stock News - GuruFocus
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Bought by Oppenheimer & Co. Inc. - Defense World
Trevi Therapeutics, Inc.(NasdaqGM: TRVI) dropped from Russell 3000 Value Index - MarketScreener
Cough in Idiopathic Pulmonary Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Algernon Pharma, Seyltx, Melius Pharma, NeRRe Therapeutics, Trevi Therapeutics - Barchart.com
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Trevi Therapeutics Stockholders Approve Key Amendments - TipRanks
Leerink Partnrs Issues Optimistic Estimate for TRVI Earnings - Defense World
Oppenheimer Raises Price Target for Trevi Therapeutics by $3 - MSN
Squarepoint Ops LLC Acquires Shares of 14,059 Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - Eastern Progress
WilmerHale Advises Trevi Therapeutics, Inc. in $115 Million Public Offering - WilmerHale
Two Sigma Advisers LP Invests $66,000 in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Two Sigma Investments LP Purchases New Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Rating Lowered to “Sell” at Wall Street Zen - Defense World
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by Millennium Management LLC - Defense World
Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com
Trevi Therapeutics Closes Public Offering - MarketScreener
Trevi Therapeutics Announces Closing of $115 Million Underwritte - GuruFocus
Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares | TRVI Stock News - GuruFocus
Trevi Therapeutics Secures Massive $115M Funding: Investors Rush to Back Chronic Cough Treatment Developer - Stock Titan
Trevi Therapeutics Announces Pricing of $100 Million Underwritte - GuruFocus
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Sold by BNP Paribas Financial Markets - Defense World
Ameriprise Financial Inc. Acquires 63,067 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Trevi Therapeutics Prices $100 Mln Public Offering Of Common Stock - Nasdaq
Trevi Therapeutics Announces Public Offering Pricing - TipRanks
Trevi Therapeutics IncExpects Cash Resources To Fund Operations Into 2029 - marketscreener.com
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock - Eastern Progress
Trevi Therapeutics Announces Proposed Public Offering of Common Stock - Longview News-Journal
Trevi Therapeutics Prices $100 Million Common Stock Offering - marketscreener.com
ProShare Advisors LLC Buys 9,589 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World
Biotech Trevi Therapeutics Secures Major $100M Financing Through Stock Offering - Stock Titan
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock | TRVI Stock News - GuruFocus
Trevi Therapeutics Announces Pricing Of $100 Million Underwritten Offering Of Common Stock - marketscreener.com
H.C. Wainwright maintains Trevi Therapeutics stock rating following trial results - Investing.com Canada
Oppenheimer Boosts Trevi Therapeutics (TRVI) PT to $23, Cites Positive Haduvio Trial Results - Insider Monkey
Stifel reiterates buy rating for Trevi Therapeutics stock after study results - Investing.com Canada
Oppenheimer Adjusts Price Target on Trevi Therapeutics to $23 From $20, Maintains Outperform Rating - marketscreener.com
Trevi Therapeutics stock soars to 52-week high of $7.43 By Investing.com - Investing.com South Africa
Trevi Therapeutics launches $100 million stock offering By Investing.com - Investing.com South Africa
Trevi Therapeutics (NASDAQ:TRVI) Given “Buy” Rating at D. Boral Capital - Defense World
Trevi Therapeutics stock soars to 52-week high of $7.43 - Investing.com India
Trevi Therapeutics Terminates ATM Prospectus with Leerink - TipRanks
3.40%
2.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):